X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (35930) 35930
Newsletter (1722) 1722
Newspaper Article (602) 602
Book Chapter (259) 259
Publication (112) 112
Dissertation (105) 105
Magazine Article (92) 92
Book / eBook (27) 27
Web Resource (21) 21
Conference Proceeding (20) 20
Reference (8) 8
Trade Publication Article (6) 6
Book Review (3) 3
Journal / eJournal (3) 3
Streaming Video (3) 3
Transcript (3) 3
Government Document (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (27146) 27146
male (11744) 11744
chronic lymphocytic-leukemia (11328) 11328
hematology (11219) 11219
female (10695) 10695
oncology (10408) 10408
chronic lymphocytic leukemia (9695) 9695
middle aged (9574) 9574
aged (8857) 8857
cancer (7044) 7044
adult (6499) 6499
leukemia (5848) 5848
leukemia, lymphocytic, chronic, b-cell - pathology (5291) 5291
research (4541) 4541
leukemia, lymphocytic, chronic, b-cell - drug therapy (4386) 4386
leukemia, lymphocytic, chronic, b-cell - genetics (4280) 4280
animals (4118) 4118
prognosis (3902) 3902
aged, 80 and over (3864) 3864
apoptosis (3503) 3503
care and treatment (3184) 3184
expression (3061) 3061
leukemia, lymphocytic, chronic, b-cell - immunology (2769) 2769
lymphoma (2717) 2717
rituximab (2601) 2601
antineoplastic agents - therapeutic use (2501) 2501
immunology (2480) 2480
cll (2472) 2472
lymphomas (2447) 2447
treatment outcome (2323) 2323
survival (2281) 2281
hemic and lymphatic diseases (2272) 2272
leukemia, lymphocytic, chronic, b-cell - metabolism (2244) 2244
leukemia, lymphocytic, chronic, b-cell - diagnosis (2218) 2218
mutation (2196) 2196
genetic aspects (2141) 2141
oncology, experimental (2109) 2109
analysis (2056) 2056
therapy (2044) 2044
leukemia, lymphocytic, chronic, b-cell - complications (1986) 1986
mice (1957) 1957
chemotherapy (1955) 1955
flow cytometry (1941) 1941
diagnosis (1919) 1919
fludarabine (1880) 1880
health aspects (1878) 1878
antineoplastic combined chemotherapy protocols - therapeutic use (1863) 1863
chronic lymphatic leukemia (1825) 1825
pathology (1792) 1792
cell biology (1785) 1785
leukemia, lymphocytic, chronic, b-cell - therapy (1748) 1748
risk factors (1743) 1743
gene expression (1520) 1520
acute lymphoblastic-leukemia (1486) 1486
non-hodgkins-lymphoma (1469) 1469
disease (1463) 1463
cell line, tumor (1450) 1450
abridged index medicus (1437) 1437
adolescent (1432) 1432
biochemistry & molecular biology (1413) 1413
pharmacology & pharmacy (1404) 1404
disease progression (1398) 1398
antineoplastic agents - pharmacology (1395) 1395
activation (1386) 1386
vidarabine - analogs & derivatives (1381) 1381
chronic lymphocytic leukaemia (1366) 1366
immunotherapy (1364) 1364
leukemia, lymphocytic, chronic, b-cell - mortality (1364) 1364
acute myeloid-leukemia (1342) 1342
immunophenotyping (1334) 1334
transplantation (1333) 1333
proteins (1331) 1331
medicine, research & experimental (1328) 1328
apoptosis - drug effects (1321) 1321
chronic myelogenous leukemia (1292) 1292
tumor cells, cultured (1287) 1287
medicine & public health (1270) 1270
b-lymphocytes - immunology (1255) 1255
lymphocytes (1254) 1254
patients (1252) 1252
cells (1239) 1239
tumors (1228) 1228
drug therapy (1217) 1217
leukemia, lymphocytic, chronic, b-cell - blood (1198) 1198
retrospective studies (1194) 1194
signal transduction (1186) 1186
lymphatic leukemia (1156) 1156
hematology, oncology and palliative medicine (1153) 1153
antibodies, monoclonal - therapeutic use (1146) 1146
development and progression (1126) 1126
chronic myeloid-leukemia (1123) 1123
medicine, general & internal (1075) 1075
in-vitro (1074) 1074
b cells (1040) 1040
child (1039) 1039
genes (1039) 1039
b-cells (1034) 1034
b-cell lymphoma (1026) 1026
b-lymphocytes - pathology (1019) 1019
chronic disease (1010) 1010
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (14) 14
Gerstein Science - Stacks (13) 13
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Credit Valley Hospital - Stacks (1) 1
St. Michael's Hospital - Circulation Desk (1) 1
St. Michael's Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (36862) 36862
French (452) 452
German (280) 280
Russian (272) 272
Spanish (248) 248
Chinese (219) 219
Polish (207) 207
Japanese (175) 175
Czech (108) 108
Italian (71) 71
Hungarian (56) 56
Portuguese (29) 29
Turkish (25) 25
Korean (22) 22
Danish (13) 13
Serbian (13) 13
Slovak (12) 12
Croatian (10) 10
Dutch (9) 9
Slovenian (9) 9
Norwegian (7) 7
Persian (7) 7
Romanian (6) 6
Hebrew (5) 5
Ukrainian (5) 5
Finnish (4) 4
Swedish (4) 4
Icelandic (2) 2
Arabic (1) 1
Bosnian (1) 1
Bulgarian (1) 1
Catalan (1) 1
Esperanto (1) 1
Galician (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2016, Volume 374, Issue 4, pp. 323 - 332
.... It had substantial antitumor effects in a phase 1–2 study involving patients with relapsed chronic lymphocytic leukemia... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2018, Volume 378, Issue 12, pp. 1107 - 1120
In a trial involving patients with relapsed or refractory chronic lymphocytic leukemia, the BCL2 inhibitor venetoclax in combination with rituximab resulted in a higher 2-year rate of progression-free... 
SURVIVAL | TRIAL | MEDICINE, GENERAL & INTERNAL | INDEPENDENT PREDICTOR | 17P DELETION | TARGETING BCL2 | PLUS RITUXIMAB | TP53 MUTATION | PROGRESSION-FREE | OPEN-LABEL | MINIMAL RESIDUAL DISEASE | Recurrence | Bendamustine Hydrochloride - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Neoplasm, Residual | Young Adult | Bendamustine Hydrochloride - administration & dosage | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Tumor Lysis Syndrome - etiology | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Rituximab - adverse effects | Kaplan-Meier Estimate | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Rituximab - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Sulfonamides - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - mortality | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Sulfonamides - administration & dosage | Treatment outcome | Chronic lymphocytic leukemia | Diagnosis | Analysis | Chronic lymphatic leukemia | Cell survival | Hematology | Leukemia | Rituximab | Clinical trials | Oncology | Chromosome deletion | Lymphatic leukemia | Patients | Cancer therapies | Evidence-based medicine | Chemotherapy | Clonal deletion | Lysis | Response rates | Bone marrow | Chromosomes | Drug dosages | Chromosome 17 | Neutropenia | Life Sciences
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 2, pp. 200 - 211
Journal Article